GlassScriptPhysician profile
Lauren A Kusznir
NPI 1073754727
$3,391.23
in general payments reported to CMS, 2019-2025
36 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $818 · 2022: $550 · 2023: $1,013 · 2024: $861 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471 · Education: $385 · Long Term Medical Supply Or Device Loan: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.87 |
| Education | $384.99 |
| Long Term Medical Supply Or Device Loan | $166.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,355.53 | 2021-2025 | Kisqali, Piqray |
| Incyte Corporation | $511.05 | 2021-2025 | Jakafi |
| Lilly USA, LLC | $205.94 | 2022-2024 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $178.32 | 2023-2024 | Injectafer, Enhertu |
| Seagen INC. | $119.20 | 2023 | Tukysa |
| Astrazeneca Pharmaceuticals LP | $109.71 | 2023-2025 | Lynparza, Calquence, Enhertu |
| Genzyme Corporation | $108.40 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $79.00 | 2023 | |
| Pfizer INC. | $62.26 | 2023-2024 | |
| Taiho Oncology, INC. | $50.19 | 2023-2024 | |
| Eisai INC. | $49.03 | 2021-2024 | |
| Myriad Genetic Laboratories, INC. | $40.78 | 2024 | Myrisk |
| Merck Sharp & Dohme LLC | $38.45 | 2024 | Keytruda, Welireg, Lynparza |
| Sobi, INC | $36.88 | 2023-2024 | |
| Array Biopharma INC | $33.84 | 2024 | Mektovi, Braftovi, Lorbrena |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $33.80 | 2024 | Zejula, Jemperli |
| Genmab U.S., INC. | $33.17 | 2024 | Tivdak |
| Servier Pharmaceuticals LLC | $32.91 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $31.96 | 2023-2024 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $21.35 | 2024 | Tavalisse, Rezlidhia |
| Abbvie INC. | $18.97 | 2024 | |
| Novocure INC. | $18.87 | 2024 | Optune |
| Ipsen Biopharmaceuticals, INC | $18.68 | 2024 | Onivyde |
| Takeda Pharmaceuticals U.S.A., INC. | $18.34 | 2024 | Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $17.99 | 2023 | Libtayo |
| Gilead Sciences, INC. | $16.56 | 2023 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $16.48 | 2023 | |
| Astellas Pharma US INC | $15.61 | 2024 | Padcev |
| Celgene Corporation | $15.00 | 2023 | Reblozyl |
| Janssen Pharmaceuticals, INC | $15.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.99 | 2023 | Opdivo |
| Mirati Therapeutics, INC. | $14.85 | 2023 | Krazati |
| Stemline Therapeutics INC. | $14.80 | 2023 | Orserdu |
| Collegium Pharmaceutical, INC. | $14.58 | 2021 | |
| Organon LLC | $14.53 | 2024 | |
| Morphosys, US INC. | $14.21 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Kusznir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.